EUVIMEDEUVIMED entdecken
Crossref

Communication of Launch Prices by Drug Companies, 2022-2024

Brian Reid, Joshua T Cohen, Pei-Jung Lin, Peter J Neumann

The American Journal of Managed Care · 2025

DOI: 10.37765/ajmc.2025.89838 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Managed Care, 2025. Verfasst von Brian Reid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Reid Strategic, 201 Maine Hwy 1 #189, Scarborough, ME 04074. Email: brian@reidstrategic.com. Hauptthemen laut MEDLINE: Drug Industry, Disclosure, Drug Costs, Communication.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To examine how drug manufacturers disclosed prices for new molecular entities approved by the FDA between 2022 and 2024. STUDY DESIGN: Retrospective study. METHODS: We included drugs approved through new drug applications or biologics license applications, excluding imaging agents, vaccines, blood products, and drugs without an assigned National Drug Code. For each drug, we assessed whether pricing was disclosed proactively (ie, in news releases or earnings calls) or reactively (ie, in media reports citing the company without prior proactive disclosure). We sourced launch prices from public disclosures and California filings. We also recorded company market capitalization, orphan drug designation, accelerated approval status, and Institute for Clinical and Economic Review assessments. RESULTS: Of 150 drugs, 107 (71%) had publicly disclosed launch prices: 49 proactively and 58 reactively. Proactive disclosure was more common among public companies with smaller market capitalizations-69% for firms worth $1 billion to $10 billion, compared with 7% for those worth more than $100 billion. CONCLUSIONS: We found that pharmaceutical companies proactively released launch prices for one-third of drugs approved from 2022 to 2024 and reactively released prices for an additional 39%. Our findings suggest that securities regulations may influence disclosure behavior, particularly for smaller public companies. Greater transparency at launch could support better-informed public discourse on drug pricing and value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryDisclosureDrug CostsCommunicationUnited StatesRetrospective StudiesHumansDrug ApprovalUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Reid Strategic, 201 Maine Hwy 1 #189, Scarborough, ME 04074. Email: brian@reidstrategic.com.

Zitieren

APA

Reid, B., Cohen, J. T., Lin, P. J., & Neumann, P. J. (2025). Communication of Launch Prices by Drug Companies, 2022-2024. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2025.89838

Vancouver

Reid B, Cohen JT, Lin PJ, Neumann PJ. Communication of Launch Prices by Drug Companies, 2022-2024. The American Journal of Managed Care. 2025. doi:10.37765/ajmc.2025.89838

BibTeX
@article{Reid2025,
  author = {Reid, Brian and Cohen, Joshua T and Lin, Pei-Jung and Neumann, Peter J},
  title = {Communication of Launch Prices by Drug Companies, 2022-2024},
  journal = {The American Journal of Managed Care},
  year = {2025},
  doi = {10.37765/ajmc.2025.89838}
}
Kostenlos starten →